IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2

T A Smirnova,L M Kravchenko,A F Komarov,O V Borovikov,E P Apalkova,E I Kleshenko,E V Borovikova,M G Kulagina,D A Kayumova

doi:10.25207/1608-6228-2017-24-4-122-127

Abstract

Aim. To determine the clinical, morphological and microbiological efficacy of treatment of gastric ulcer associated with Helicobacter pylori, using recombinant interleukin-2 "Roncoleukin" without antibiotics. Materials and methods . 108 patients suffering from HP-associated gastric ulcer disease were randomly divided into two groups. The I group of patients was cured with standard three or four component methods of therapy included proton pomp inhibitors and two antibiotics (usually Klaritromycin and Amoxicillin). Patients of the second group were treated with the same therapy, but instead of antibiotics they received 0,1 mg rIL-2 – Roncoleukin into four – six points submucously using gastroscope techniques and 0,4 mg was dissolved in 400 ml 0,9% NaCl and infused intravenously. This procedure was performed three times with the interval of 72 hours. Results. One month after the end of treatment it was found that in the group treated with rIL-2 the HP eradication achieved in 95,4% in comparison to 81,5% in control patients. In Roncoleukin treated group ulcer epithelization period was 10,79±0,46 days and in traditionally treated group – 35,23±1,58 days. In third month of monitoring in gastric mucosae bioptates of basic group patients in 93,5% there were no morphological inflammatory signs and in 81,4% of patients intestinal metaplasia disappiered. Conclusion. The proposed method of complex treatment of gastric ulcer associated with Helicobacter pylori is clinically and pathogenetically justified.

Highlights

Материалы и методы. 108 человек, страдающих ЯБЖ, ассоциированной с НР, были рандомизированно разделены на две группы
Materials and methods. 108 patients suffering from Helicobacter pylori (HP)-associated gastric ulcer disease were randomly divided into two groups
Patients of the second group were treated with the same therapy, but instead of antibiotics they received 0,1 mg rIL-2 – Roncoleukin into four – six points submucously using gastroscope techniques and 0,4 mg was dissolved in 400 ml 0,9% NaCl and infused intravenously

Summary

ОРИГИНАЛЬНЫЕ СТАТЬИ

ИММУНОТЕРАПИЯ ЯЗВЕННОЙ БОЛЕЗНИ ЖЕЛУДКА, АССОЦИИРОВАННОЙ С HELICOBACTER PYLORI ПРЕПАРАТОМ. Определить клинико-морфологическую и микробиологическую эффективность лечения язвенной болезни желудка, ассоциированной с Helicobacter pylori, препаратом рекомбинантного IL-2 – «Ронколейкин» без применения антибактериальных препаратов. Предлагаемый метод комплексного лечения язвенной болезни желудка, ассоциированной с Helicobacter pylori, является эффективным, клинически и патогенетически обоснованным. Ключевые слова: язвенная болезнь желудка, Heliсobacter pylori, препарат рекомбинантного IL-2. Смирнова Т.А., Боровиков О.В., Клещенко Е.И., Кулагина М.Г., Каюмова Д.А., Комаров А.Ф., Боровикова Е.В., Апалькова Е.П., Кравченко Л.М. Иммунотерапия язвенной болезни желудка, ассоциированной с Helicobacter pylori препаратом рекомбинантного IL-2. For citation: Smirnova T.A., Borovikov O.V., Kleshenko E. IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2.

Materials and methods

Results

Conclusion

Результаты и обсуждение